Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Czock

Showing results (61-70 of 104) with videos related to

Pageof 11
Sort By:
Emerging Infectious Diseases|October 22, 2004
Thrombocytopenia and acute renal failure in Puumala hantavirus infectionsFranz Maximilian Rasche, Boris Uhel, Detlev H Krüger, et al.
British Journal of Clinical Pharmacology|June 19, 2013
CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scoresAlbader Albarmawi, David Czock, Annika Gauss, et al.
International Journal of Medical Informatics|February 4, 2014
What, if all alerts were specific - estimating the potential impact on drug interaction alert burdenHanna M Seidling, Ulrike Klein, Matthias Schaier, et al.
Clinical Pharmacology in Drug Development|January 4, 2024
Effect of Tacrolimus Formulation (Prolonged-Release vs Immediate-Release) on Its Susceptibility to Drug-Drug Interactions with St. John's WortKatja S Gümüs, Anna Teegelbekkers, Max Sauter, et al.
Drugs & Aging|February 6, 2024
Development and Pilot Testing of an Algorithm-Based Approach to Anticholinergic Deprescribing in Older PatientsTanja Wehran, Annette Eidam, David Czock, et al.
Frontiers in Pharmacology|April 24, 2023
Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteersVanessa Zhu, Jürgen Burhenne, Johanna Weiss, et al.
BMC Pharmacology & Toxicology|August 30, 2019
Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathwaysAndrea Huppertz, Caspar Grond-Ginsbach, Chris Dumschat, et al.
European Journal of Drug Metabolism and Pharmacokinetics|December 20, 2023
Evaluation of Hydroxychloroquine as a Perpetrator on Cytochrome P450 (CYP) 3A and CYP2D6 Activity with Microdosed Probe Drugs in Healthy VolunteersFelicitas Stoll, Antje Blank, Gerd Mikus, et al.
Frontiers in Pharmacology|April 28, 2025
Effect of the frequently used antiepileptic drugs carbamazepine, gabapentin, and pregabalin on the pharmacokinetics of edoxaban and other oral factor xa inhibitors in healthy volunteersAlexander Lenard, Simon A Hermann, Felicitas Stoll, et al.
Drugs & Aging|January 13, 2023
Frailty as a Marker for the Plasma Concentrations of Direct Oral Anticoagulants in Older Patients: Results of an Exploratory StudyAnnette Eidam, Julian Marji, Petra Benzinger, et al.
Pageof 11

Showing results (61-70 of 104) with videos related to

Sort By:
Pageof 11
Emerging Infectious Diseases|October 22, 2004
Thrombocytopenia and acute renal failure in Puumala hantavirus infectionsFranz Maximilian Rasche, Boris Uhel, Detlev H Krüger, et al.
British Journal of Clinical Pharmacology|June 19, 2013
CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scoresAlbader Albarmawi, David Czock, Annika Gauss, et al.
International Journal of Medical Informatics|February 4, 2014
What, if all alerts were specific - estimating the potential impact on drug interaction alert burdenHanna M Seidling, Ulrike Klein, Matthias Schaier, et al.
Clinical Pharmacology in Drug Development|January 4, 2024
Effect of Tacrolimus Formulation (Prolonged-Release vs Immediate-Release) on Its Susceptibility to Drug-Drug Interactions with St. John's WortKatja S Gümüs, Anna Teegelbekkers, Max Sauter, et al.
Drugs & Aging|February 6, 2024
Development and Pilot Testing of an Algorithm-Based Approach to Anticholinergic Deprescribing in Older PatientsTanja Wehran, Annette Eidam, David Czock, et al.
Frontiers in Pharmacology|April 24, 2023
Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteersVanessa Zhu, Jürgen Burhenne, Johanna Weiss, et al.
BMC Pharmacology & Toxicology|August 30, 2019
Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathwaysAndrea Huppertz, Caspar Grond-Ginsbach, Chris Dumschat, et al.
European Journal of Drug Metabolism and Pharmacokinetics|December 20, 2023
Evaluation of Hydroxychloroquine as a Perpetrator on Cytochrome P450 (CYP) 3A and CYP2D6 Activity with Microdosed Probe Drugs in Healthy VolunteersFelicitas Stoll, Antje Blank, Gerd Mikus, et al.
Frontiers in Pharmacology|April 28, 2025
Effect of the frequently used antiepileptic drugs carbamazepine, gabapentin, and pregabalin on the pharmacokinetics of edoxaban and other oral factor xa inhibitors in healthy volunteersAlexander Lenard, Simon A Hermann, Felicitas Stoll, et al.
Drugs & Aging|January 13, 2023
Frailty as a Marker for the Plasma Concentrations of Direct Oral Anticoagulants in Older Patients: Results of an Exploratory StudyAnnette Eidam, Julian Marji, Petra Benzinger, et al.
Pageof 11